PAP
SYRE icon

Persistent Asset Partners’s Spyre Therapeutics SYRE Stock Holding History

Persistent Asset Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$778K Buy
8,760
+3,957
+82% +$289K 0.23% 80
2026
Q1 		$242K Buy
4,803
+2,557
+114% +$96.4K 0.09% 176
2025
Q4 		$73.6K Buy
+2,246
New +$58.7K 0.03% 281

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Persistent Asset Partners's SYRE Position: Q2 2026 in Review

Persistent Asset Partners increased its Spyre Therapeutics (SYRE) stake by 82% in Q2 2026, buying an estimated $289K and bringing the position to 8,760 shares worth $778K. The position accounts for 0.23% of the portfolio, ranked #80.

Persistent Asset Partners first reported a position in SYRE in Q4 2025 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Persistent Asset Partners held 8,760 shares of Spyre Therapeutics worth $778K as of Q2 2026.
  • Persistent Asset Partners bought 3,957 Spyre Therapeutics shares in Q2 2026, an estimated $289K.
  • Spyre Therapeutics made up 0.23% of Persistent Asset Partners's portfolio in Q2 2026, its #80 holding.
  • Persistent Asset Partners first reported a position in Spyre Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.